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Introduction
Pityriasis rubra pilaris (PRP) is a rare inflammatory dermatosis of 
unknown origin and considerable clinical heterogeneity (1). It has 
been divided into six types, each with a particular clinical presen-
tation, age of onset, and course (2). Type IV, or the circumscribed 
juvenile form, accounts for approximately 25% of cases of PRP (2). 
It usually occurs in prepubertal children and its main features are 
hyperkeratotic perifollicular papules forming sharply demarcated 
erythematous plaques, localized to the elbows, knees, and dor-
sal aspects of the hands and feet. An orange palmoplantar kera-
toderma is frequently present (3). Due to the clinical variability 
observed in this disease, the treatment is challenging and the re-
sponse is variable, making it difficult to predict the outcome of 
the treatment. A standard therapeutic approach does not exist be-
cause the cases are few and treatment is protracted. Retinoids are 
among the most frequently used medications and have variable 
effectiveness (1).
Case report
A 19-year-old male patient was observed in our department due to 
a 2-week, mildly pruriginous eruption affecting his elbows, knees, 
and palmoplantar regions. He mentioned taking ibuprofen 400 
mg for sore throat 1 week before the onset of the dermatosis. His 
past medical record was otherwise irrelevant and he had no fami-
ly history of other skin diseases, including psoriasis or ichthyosis.
Upon physical examination, the patient had circumscribed, 
well-defined, scaling salmon plaques, distributed symmetrically 
on the elbows, knees, and dorsal aspects of the hands and feet, 
along with an orange keratoderma (Fig. 1a–c). No mucosal lesions 
(specifically, in the buccal mucosa) or nail changes were found.
A skin biopsy was performed, revealing alternating orthokera-
tosis and parakeratosis, confluent hypergranulosis, and follicular 
plugging, compatible with the clinical diagnosis of pityriasis ru-
bra pilaris. The patient’s weight was 70 kg. Due to the extent of the 
lesions and the impact they were having on the patient, he was 
medicated with acitretin, 25 mg every other day. No topical treat-
ment was prescribed. One month after beginning the treatment, 
there was already a marked improvement of the dermatosis (Fig. 
1d–f). After 6 months, the lesions had completely resolved and 
acitretin was stopped (Fig. 1g–i). The treatment was very well tol-
erated by the patient, with the only side effect being mild dryness 
of the lips. The lesions have not recurred after 1 year of follow-up.
Discussion
PRP is a chronic papulosquamous disorder characterized by red-
dish-orange scaly plaques, palmoplantar keratoderma, and kera-
totic follicular papules (1). The disease may progress to erythro-
derma with distinct areas of uninvolved skin, known as “islands 
of sparing” (1).
It has an estimated incidence of 1:3,500–5,000 patients and af-
fects individuals of all racial backgrounds equally, with no gender 
predilection (1).
Although its pathogenesis is still unknown, some conditions 
such as abnormalities in vitamin A metabolism leading to vita-
min-A deficiency, infections, trauma, impaired immunologic re-
sponse, rheumatism, and malignancy have been implicated (4).
Histology helps in making the diagnosis by excluding other 
dermatoses such as psoriasis; however, it is not pathognomonic. 
Hyperkeratosis with alternating orthokeratosis and parakeratosis 
forming a checkerboard pattern in the stratum corneum, focal or 
confluent hypergranulosis, follicular plugging with perifollicu-
lar parakeratosis forming a shoulder effect, thick suprapapillary 
plates, broad rete ridges, narrow dermal papillae, and sparse su-
perficial dermal lymphocytic perivascular infiltration are frequent 
findings (5).
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There are multiple treatment options for this entity. Because 
there are no controlled trials to evaluate the efficacy and safety of 
treatments in patients with PRP, the use of these agents is based 
on clinical reports. There have been reports on the use of topical 
agents such as corticosteroids and vitamin D derivates, vitamin 
A, photo(chemo)therapy, and systemic therapies such as systemic 
retinoids, azathioprine, methotrexate, cyclosporine, and biologi-
cal agents (6, 7).
Systemic retinoids are one of the first-line treatments for this 
condition (8). Dicken reported that, out of 15 patients with PRP 
treated with oral retinoids, 10 had complete clearing of the lesions 
and two had partial clearing after 4 to 6 months of therapy (6). 
The recommended dose of oral acitretin is 0.5 to 0.75 mg/kg/day 
(8). Response to retinoid therapy is usually evident within 3 to 
6 months, although longer courses of treatment are necessary in 
some patients (6). In our case, we decided to use acitretin because 
its use in this disease is better documented than isotretinoin and 
allitretinoin.
As is known, retinoids produce a number of side effects that 
are dose-related. These include alopecia, cheilitis or chapped 
lips, dermatitis, epistaxis, nail fragility, peeling rash, xerosis and 
pruritus, dryness of the eyes, which may result in discomfort, 
photophobia, blepharoconjunctivitis, and keratitis (9). In our 
case, the patient was treated with a low-dose regimen of acitretin, 
which was effective and well tolerated. This highlights the option 
of using lower doses of retinoids in type IV PRP, reducing the risk 
of drug-related side effects and non-adherence by the patient.
Finally, this is a case of a late onset type IV PRP, which usu-
ally occurs in prepubertal children, showing that it can also affect 
young adults.
Figure 1 | Clinical aspect of the lesions (a–c: right palm, right elbow, and right knee before treatment, respectively; d–f: right palm, right elbow, and right knee 1 
month after beginning treatment, respectively; g–i: right palm, right elbow, and right knee 6 months after beginning treatment, respectively).
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